TERN Terns Pharmaceuticals, Inc. Common Stock

XNAS 52.97 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TERN $52.97 —
Key stats
$52.97
52-Week Range
$6.99 – $53.19
YTD
+32.05%
IV Rank (30D)
5.6
Straddle Price
$8.00
P/C Vol Ratio
3.41
Market Cap
$6.1B
Open
$52.97
Day Range
$52.94 – $52.98
Volume
6,347,046
Prev Close
$52.93
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$6.1B
Employees
59
List Date
2021-02-05
CIK
0001831363
Headquarters
Foster City, CA
Homepage
https://www.ternspharma.com

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The compa…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
Insufficient price history — listed 2085 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $52.78
SMA 50: $49.21
SMA 200: $27.75
Current: $52.95
EMA 12: $52.82
EMA 26: $51.86
MACD: 0.9616 | Signal: -0.3121
BULLISH
ADX (14): 49.31
STRONG TREND
+DI: 29.45
−DI: 8.99

Momentum Oscillators

RSI (14): 73.93
OVERBOUGHT
Stoch %K: 90.09
Stoch %D: 89.28
Williams %R: -8.11

Volume & Volatility

BB Upper: $53.05
BB Lower: $52.51
NEUTRAL
OBV: 187,205,935
Vol SMA 20: 6,318,501
Vol ROC: 52.84%
ATR: $0.43
True Range: $0.05
HV 20: 2.0%
HV 30: 17.6%
HV 60: 31.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-05-06T00:00:00 – 2026-05-04T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary Overall Assessment: NEUTRAL (6/10) Key Drivers: Recent news headlines, technical indicators Primary Risks: Market sentiment, options market signals Investment Thesis: Terns Pharmaceuticals' acquisition by Merck could drive growth, but recent news headlines and options market signals indicate mixed sentiment. Recent News Sentiment Impact: Positive news headlines outweigh negative ones, suggesting a potential catalyst for the stock.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Bullish momentum
  • Medium-term (1-3 months): Uptrend
  • Long-term (3-12 months): Uptrend

Support/Resistance Levels:

  • Upper Bollinger Band: $53.05
  • Middle Line: $52.78
  • Lower Bollinger Band: $52.51

Momentum Signals:

  • RSI: Overbought (>70), suggests potential for a correction or consolidation.
  • MACD: Bullish crossover, indicating strong momentum.
  • Bollinger Bands: Neutral signal.

Volume Analysis:

  • Volume SMA 20: Increasing trend
  • On-Balance Volume (OBV): Strong uptrend
  • Volume Rate of Change: Moderate increase

News & Sentiment Analysis

Recent Headlines Summary:

  • Merck's acquisition of Terns Pharmaceuticals received positive sentiment from news headlines.
  • Some negative sentiments emerged, but overall, the tone is bullish.

Sentiment Assessment: Aggregate news sentiment: POSITIVE (60%)

Catalyst Identification:

  • Upcoming earnings reports and pipeline updates from Merck and Terns Pharmaceuticals
  • Regulatory changes and approvals for new treatments

Market Narrative: Recent news headlines align with technical signals, indicating a potential catalyst for the stock. However, options market signals suggest mixed sentiment.

Risk & Volatility Assessment

Beta Interpretation: Low risk (0.14 vs SPY)

Volatility Regime:

  • Current volatility: 1.12
  • Historical volatility: HV20 2.0%, HV30 17.6%, HV60 31.1%
  • IV Premium vs HV30: 205.5% (positive), indicating implied richer than realized

Options Market Signals: IV Rank: Low (0.5%), suggesting historically low volatility. Current IV: 53.7%

Downside Protection:

  • Support levels: Lower Bollinger Band ($52.51) and SMA 20 ($49.21)
  • Risk management considerations: Monitor volume and sentiment indicators for potential reversals.

Market Context & Positioning

Sector Performance: Relative strength vs sector/market: Positive (0.5%)

Institutional Activity: Volume patterns suggesting institutional interest: Increasing trend

Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.02, indicating low correlation.

Relative Valuation: Position within trading range: Mid-range

Key Levels & Action Items

Critical Price Levels:

  • Support/resistance levels from technical indicators
  • Recent price highs and lows

Breakout/Breakdown Levels: Technical levels that could trigger significant moves:

  • Upper Bollinger Band ($53.05)
  • Middle Line ($52.78)

Time-Sensitive Catalysts: Earnings reports, pipeline updates, regulatory changes, and approvals.

Risk Management: Stop-loss levels: Monitor volume and sentiment indicators for potential reversals. Position sizing considerations: Gradually increase exposure as the stock approaches support/resistance levels.

This comprehensive analysis provides a balanced view of Terns Pharmaceuticals' stock performance, incorporating technical indicators, recent news headlines, options market signals, and risk assessment criteria.

Generated
Earnings History
12 of 12 under expected move
Avg Expected Move
27.98%
Avg Actual Move
4.14%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-05-15 Pre-Market 31.60% 6.24% 0.20x Within
2023-08-08 Pre-Market 31.98% 4.95% 0.15x Within
2023-11-14 Pre-Market 26.71% 5.34% 0.20x Within
2024-03-14 Pre-Market 15.54% 5.23% 0.34x Within
2024-05-13 Pre-Market 10.43% 5.94% 0.57x Within
2024-08-05 Pre-Market 44.57% 2.01% 0.05x Within
2024-11-12 After-Close 13.25% 5.44% 0.41x Within
2025-03-20 Pre-Market 69.62% 0.63% 0.01x Within
2025-05-08 Pre-Market 35.54% 0.83% 0.02x Within
2025-08-05 Pre-Market 28.26% 5.74% 0.20x Within
2025-11-10 Pre-Market 15.97% 3.52% 0.22x Within
2026-01-09 After-Close 12.33% 3.86% 0.31x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TERN Options Activity & IV Rank

TERN IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 10.9%
7-DTE IV: 10.9%
Expected Move: $8.00
7-DTE Move: $0.57
Days to Exp: 45 (2026-06-18)

Options Flow

Call Volume: 143
Put Volume: 488
P/C Volume: 3.413
BEARISH
Call OI: 43,347
Put OI: 10,696
P/C OI: 0.247
Total OI: 54,043

ATM Options Pricing

ATM Call: $0.50
ATM Put: $7.50
Call %: 0.9%
Put %: 14.2%

Chain Summary

Chain Volume: 5,195
Chain OI: 190,953
Last Updated: 5/4/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 94th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
94%
vs own history
GEX tilt
+0.70
OI-weighted, today
Vanna tilt
+0.95
δ-sensitivity to IV
Charm tilt
-0.94
δ-decay vs time
Vanna tilt +0.95: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.94: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 49 ATM contracts, 162k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of May 4 · No data
30 DTE / 10d —
— pts EXTREME
as of May 4 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)0.5LowMay 4
IV Rank (30 DTE)5.6LowMay 4
Straddle Price (30 DTE)$8.00May 4
Beta Analysis
Insufficient price history — listed 2085 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

TERN Institutional Ownership (13F)

Latest filings — 2026-06-30
Diluted shares outstanding: 91,979,271 (as of 2025-12-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

9 filers7,171,550 shares$309.91M value7.80% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 5,523,948 $223.17M 72.01% 6.01% 2025-12-31
2 Janus Henderson Group plc 1,470,057 $77.51M 25.01% 1.60% 2026-03-31
3 CIBRA Capital Ltd 151,440 $7.98M 2.58% 0.16% 2026-03-31
4 MIZUHO SECURITIES USA LLC 11,083 $584.30K 0.19% 0.01% 2026-06-30
5 CIBC WORLD MARKETS CORP 5,674 $229.23K 0.07% <0.01% 2025-12-31
6 CWM, LLC Custodian 4,172 $219.95K 0.07% <0.01% 2026-03-31
7 CIBC Private Wealth Group LLC 5,000 $202.00K 0.07% <0.01% 2025-12-31
8 COMERICA BANK Custodian 105 $4.24K <0.01% <0.01% 2025-12-31
9 Sunbelt Securities, Inc. 71 $3.74K <0.01% <0.01% 2026-03-31
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

TERN Insider Trading (Form 4)

Latest: 2026-05-05
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-05-05 Heather D Turner Director Disp (D) −110,697 opt — EDGAR
2026-05-05 Jeffrey B Kindler Director Disp (D) −208,505 opt — EDGAR
2026-05-05 Jill M. Quigley Director Disp (D) −147,309 opt — EDGAR
2026-05-05 David A Fellows Director Disp (D) −221,136 opt — EDGAR
2026-05-05 Amy L. Burroughs Chief Executive Officer Mixed −304,933 $53.00 -$16.16M EDGAR
2026-05-05 Robert Azelby Director Disp (D) −91,697 opt — EDGAR
2026-05-05 Emil Kuriakose Chief Medical Officer Mixed −106,515 $53.00 -$5.65M EDGAR
2026-05-05 Andrew Gengos Chief Financial Officer Mixed −109,253 $53.00 -$5.79M EDGAR
2026-05-05 Radhika Tripuraneni Director Disp (D) −190,030 opt — EDGAR
2026-04-02 Emil Kuriakose Chief Medical Officer Sell (S) −942 $52.75 -$49.7K EDGAR
2026-03-17 Amy L. Burroughs Chief Executive Officer Mixed — $25.67 -$613.4K EDGAR
2026-02-18 Amy L. Burroughs Chief Executive Officer Mixed — $21.92 -$503.9K EDGAR
2026-02-02 Heather D Turner Director Grant (A) +1,697 opt — EDGAR
2026-02-02 Robert Azelby Director Grant (A) +1,697 opt — EDGAR
2026-02-02 Jill M. Quigley Director Grant (A) +1,697 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TERN Insider Holdings

4 insiders · @ $52.95
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Hongbo Lu Director 476,190 $25.21M $19.64M 11 2025-06-12
2 Mark J. Vignola Chief Financial Officer 83,811 $4.44M -$159.6K 10 2025-01-06
3 Jill M. Quigley Director 24,520 $1.30M -$961.4K 15 2026-05-05
4 Melita Sun Jung Chief Business Officer 2,250 $119.1K $11.5K 2 2025-02-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TERN Board & Officers

As of SEC filings through May 5, 2026

Directors 1

Changes in the last 10 years (67)
May 5, 2026Robert Azelby reported in an SEC filing no longer being a director
May 5, 2026Radhika Tripuraneni reported in an SEC filing no longer being a director
May 5, 2026Jill M. Quigley reported in an SEC filing no longer being a director
May 5, 2026Jeffrey B Kindler reported in an SEC filing no longer being a director
May 5, 2026Heather D Turner reported in an SEC filing no longer being a director
May 5, 2026Emil Kuriakose reported in an SEC filing no longer being Chief Medical Officer
May 5, 2026David A Fellows reported in an SEC filing no longer being a director
May 5, 2026Andrew Gengos reported in an SEC filing no longer being Chief Financial Officer
May 5, 2026Amy L. Burroughs reported in an SEC filing no longer being a director
May 5, 2026Amy L. Burroughs reported in an SEC filing no longer being Chief Executive Officer
Feb 24, 2025Andrew Gengos became Chief Financial Officer
Feb 22, 2025The company announced the departure of David Eric Strauss as Principal Accounting Officer in an SEC filing
Feb 20, 2025The company announced the departure of Carl L Gordon from the board in an SEC filing
Feb 20, 2025Robert Azelby became a director
Feb 1, 2025David Eric Strauss became Principal Accounting Officer
Nov 18, 2024Heather D Turner became a director
Nov 14, 2024The company announced the departure of Ann Elizabeth Taylor from the board in an SEC filing
Jul 23, 2024The company announced the departure of Seokho Bryan Yoon as COO and General Counsel in an SEC filing
Jul 23, 2024The company announced the departure of Mark J. Vignola as Chief Financial Officer in an SEC filing
Jun 14, 2024Jill M. Quigley no longer listed as Sr. Advisor & Strategy Officer in SEC filings
Not reported recently (16)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TERN Proposed Insider Sales (Form 144)

Latest: 2026-01-15
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-01-15 AMY BURROUGHS Director, Officer 97,915 $3.64M 2026-01-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-11-04 JILL QUIGLEY Director 24,520 $344.0K 2025-11-04 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-01-06 MARK J VIGNOLA Officer 9,059 $52.1K 2025-01-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2025-01-06 JILL QUIGLEY Director 8,760 $50.4K 2025-01-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-09-10 SEOKHO BRYAN YOON Officer 10,000 $91.2K 2024-09-10 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-09-10 MARK J VIGNOLA Officer 10,000 $91.2K 2024-09-10 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-09-09 JILL QUIGLEY Officer 8,857 $69.2K 2024-09-09 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-07-15 JILL QUIGLEY Director, Officer 32,000 $297.9K 2024-07-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-07-15 OrbiMed Asia Partners III, LP Director, Shareholder 131,700 $1.23M 2024-07-15 TD Cowen — EDGAR
2024-07-15 OrbiMed Private Investments VII, LP Director, Shareholder 976,800 $9.09M 2024-07-15 TD Cowen — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.03
TTM Revenue
—
TTM Net Income
$-96.21M
TTM Op. Cash Flow
$-82.18M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '252025-12-31—$-23.57M$-0.24$-19.08M
Q3 '252025-09-30—$-24.64M$-0.27$-19.77M
Q2 '252025-06-30—$-24.09M$-0.26$-18.88M
Q1 '252025-03-31—$-23.91M$-0.26$-24.44M
Q4 '242024-12-31—$-21.80M$-0.23$-14.58M
Q3 '242024-09-30—$-21.95M$-0.28$-16.45M
Q2 '242024-06-30—$-22.74M$-0.31$-16.18M
Q1 '242024-03-31—$-22.37M$-0.30$-22.80M
Q4 '232023-12-31—$-21.02M$-0.29$-19.32M
Q3 '232023-09-30—$-29.77M$-0.42$-20.70M
Q2 '232023-06-30—$-17.90M$-0.25$-12.99M
Q1 '232023-03-31—$-21.53M$-0.31$-14.38M
Q4 2025 • period ending 2025-12-31 • filed 2026-03-30
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-9.6%
ROA
-9.4%
Div Yield
0.00%
FCF Yield
—
Debt/Equity
0.00
Current Ratio
—
Market Cap
$0.00
as of 2026-05-05
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
5.54M
SI % of Float
4.92%
Days to Cover
1.46
Short Vol Ratio
34.9%
Free Float
112.45M
Float %
97.3%
Short interest 2026-04-30 • Short volume 2026-05-04 • Float 2026-04-17